Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Revolution Medicines advances daraxonrasib NDA and reports new lung cancer combination dataAug 5Quarterly updatedaraxonrasibRevolution Medicines, Inc.